Abstract

High-throughput CRISPR-Cas9 knockout screens using a tiling-sgRNA design permit in situ evaluation of protein domain function. Here, to facilitate de novo identification of essential protein domains from such screens, we propose ProTiler, a computational method for the robust mapping of CRISPR knockout hyper-sensitive (CKHS) regions, which refer to the protein regions associated with a strong sgRNA dropout effect in the screens. Applied to a published CRISPR tiling screen dataset, ProTiler identifies 175 CKHS regions in 83 proteins. Of these CKHS regions, more than 80% overlap with annotated Pfam domains, including all of the 15 known drug targets in the dataset. ProTiler also reveals unannotated essential domains, including the N-terminus of the SWI/SNF subunit SMARCB1, which is validated experimentally. Surprisingly, the CKHS regions are negatively correlated with phosphorylation and acetylation sites, suggesting that protein domains and post-translational modification sites have distinct sensitivities to CRISPR-Cas9 mediated amino acids loss.

Tiling-sgRNA designs allow the in situ evaluation of protein domain functions. Here the authors present ProTiler - a computational method to predict CRISPR knockout hyper-sensitive regions, revealing previously unannotated domains.

Details

Title
De novo identification of essential protein domains from CRISPR-Cas9 tiling-sgRNA knockout screens
Author
He, Wei 1 ; Zhang, Liang 1 ; Villarreal, Oscar D 1 ; Fu Rongjie 1 ; Bedford, Ella 1 ; Dou Jingzhuang 1 ; Patel, Anish Y 1   VIAFID ORCID Logo  ; Bedford, Mark T 2   VIAFID ORCID Logo  ; Shi, Xiaobing 3   VIAFID ORCID Logo  ; Chen, Taiping 2   VIAFID ORCID Logo  ; Bartholomew, Blaine 2   VIAFID ORCID Logo  ; Xu, Han 4 

 The University of Texas MD Anderson Cancer Center, Department of Epigenetics and Molecular Carcinogenesis, Smithville, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776) 
 The University of Texas MD Anderson Cancer Center, Department of Epigenetics and Molecular Carcinogenesis, Smithville, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776); The University of Texas MD Anderson Cancer Center, The Center for Cancer Epigenetics, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776) 
 Van Andel Research Institute, Center for Epigenetics, Grand Rapids, USA (GRID:grid.251017.0) (ISNI:0000 0004 0406 2057) 
 The University of Texas MD Anderson Cancer Center, Department of Epigenetics and Molecular Carcinogenesis, Smithville, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776); The University of Texas MD Anderson Cancer Center, The Center for Cancer Epigenetics, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776); The University of Texas MD Anderson Cancer Center, Department of Bioinformatics and Computational Biology, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776) 
Publication year
2019
Publication date
Dec 2019
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2300955293
Copyright
This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.